Shares in medical research company Pacific Edge surged nearly 50 per cent to a new all-time high last night after the company struck its second US deal in less than a week.
Pacific Edge yesterday signed an agreement with medical network solution company, the America's Choice Provider Network (ACPN), giving the US firm use of its bladder cancer test, Cxbladder. It comes after Pacific Edge said last Friday that it had secured an agreement with medical provider FedMed.
It also won the supreme award at the New Zealand Innovators Awards last week - more good news for a company that reported a loss of $6.9 million for the latest financial year.
"It's been a pretty amazing week all round and it's great for the company to be getting traction in the US market, and for our shareholders," said chief executive David Darling.
Pacific Edge shares have gained more than 110 per cent since October 15 to close at $1.06 last night.